Ilona Tadulewicz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ilona Tadulewicz has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
- Aleksandra Kozłowska
University Clinical Centre in Gdańsk, Poland
4 shared publications - Anna Kocik
Lazarski University, Warsaw, Poland
4 shared publications - Mateusz Drozd
Medical University of Gdansk, Poland
4 shared publications - Natalia Nowak
University Clinical Centre in Gdańsk, Poland
4 shared publications - Zuzanna Butkowska
Medical University of Gdansk, Poland
4 shared publications - Łucja Komisarczyk
University Clinical Centre in Gdańsk, Poland
4 shared publications
Latest Publications
- Open Access
- 30 June 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 5 (2(50))
THE NEW UNDERSTANDING OF AUTISM - A LITERATURE REVIEW
Introduction: Autism spectrum disorder (ASD) is a neurodevelopmental condition characterized by marked heterogeneity in clinical presentation, genetic architecture, and developmental trajectories. Traditional models conceptualizing ASD as a single disorder have increasingly failed to explain the broad variability observed among affected individuals. Recent advances in genomics, epidemiology, and developmental neuroscience suggest that ASD comprises multiple biologically distinct phenotypes shaped by complex interactions between genetic susceptibility, environmental exposures, and developmental timing. The aim of this review was to synthesize current evidence on the most probable genetic, epigenetic, and environmental mechanisms underlying the development and manifestation of ASD, with particular emphasis on recent large-scale studies identifying distinct autism phenotypes and their associated risk factors. Materials and Methods: A narrative review of the literature was conducted using structured searches of PubMed and Google Scholar. Peer-reviewed articles published in English up to January 1, 2026 were included. Priority was given to large-scale genomic studies, meta-analyses, and population-based epidemiological investigations examining genetic architecture, phenotypic stratification, developmental timing, and environmental risk factors associated with ASD. Results: The reviewed evidence indicates that ASD is best conceptualized as a group of related but biologically heterogeneous neurodevelopmental conditions rather than a single disorder. Data-driven analyses have identified four major autism phenotypes supported by distinct patterns of common and rare genetic variation and class-specific developmental gene expression profiles. ASD risk is highly polygenic, involving cumulative effects of numerous common variants alongside rare inherited and de novo mutations. Environmental factors, including maternal metabolic and endocrine disorders, infections, and exposure to environmental pollutants, contribute to ASD risk, although many associations are substantially influenced by familial confounding. Additionally, developmental timing plays a critical role, as genetic liability influences not only ASD risk but also age at diagnosis and clinical presentation across the lifespan. Conclusions: Current evidence supports a multidimensional and developmental model of ASD in which genetic susceptibility, environmental exposures, and developmental processes interact to produce diverse phenotypic outcomes. The identification of distinct autism phenotypes enables a more personalized approach to patient care and provides a foundation for the development of phenotype-specific diagnostic, personalized risk assessment and therapeutic strategies. Advances in research methodologies and diagnostic technologies allow for earlier and more accurate identification of individuals at risk, facilitating timely intervention. Furthermore, continued discovery of novel genetic variants and their functional consequences may enable targeted treatments aimed at improving outcomes for individuals affected by ASD. These findings underscore the importance of enhanced prenatal care, including monitoring and management of maternal risk factors, to support optimal neurodevelopment. Future research should prioritize integrative, genetically informed approaches to further elucidate causal mechanisms and advance precision medicine in autism.
- 30 June 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 5 (2(50))
Open AccessTHE NEW UNDERSTANDING OF AUTISM - A LITERATURE REVIEW
Introduction: Autism spectrum disorder (ASD) is a neurodevelopmental condition characterized by marked heterogeneity in clinical presentation, genetic architecture, and developmental trajectories. Traditional models conceptualizing ASD as a single disorder have increasingly failed to explain the broad variability observed among affected individuals. Recent advances in genomics, epidemiology, and developmental neuroscience suggest that ASD comprises multiple biologically distinct phenotypes shaped by complex interactions between genetic susceptibility, environmental exposures, and developmental timing. The aim of this review was to synthesize current evidence on the most probable genetic, epigenetic, and environmental mechanisms underlying the development and manifestation of ASD, with particular emphasis on recent large-scale studies identifying distinct autism phenotypes and their associated risk factors. Materials and Methods: A narrative review of the literature was conducted using structured searches of PubMed and Google Scholar. Peer-reviewed articles published in English up to January 1, 2026 were included. Priority was given to large-scale genomic studies, meta-analyses, and population-based epidemiological investigations examining genetic architecture, phenotypic stratification, developmental timing, and environmental risk factors associated with ASD. Results: The reviewed evidence indicates that ASD is best conceptualized as a group of related but biologically heterogeneous neurodevelopmental conditions rather than a single disorder. Data-driven analyses have identified four major autism phenotypes supported by distinct patterns of common and rare genetic variation and class-specific developmental gene expression profiles. ASD risk is highly polygenic, involving cumulative effects of numerous common variants alongside rare inherited and de novo mutations. Environmental factors, including maternal metabolic and endocrine disorders, infections, and exposure to environmental pollutants, contribute to ASD risk, although many associations are substantially influenced by familial confounding. Additionally, developmental timing plays a critical role, as genetic liability influences not only ASD risk but also age at diagnosis and clinical presentation across the lifespan. Conclusions: Current evidence supports a multidimensional and developmental model of ASD in which genetic susceptibility, environmental exposures, and developmental processes interact to produce diverse phenotypic outcomes. The identification of distinct autism phenotypes enables a more personalized approach to patient care and provides a foundation for the development of phenotype-specific diagnostic, personalized risk assessment and therapeutic strategies. Advances in research methodologies and diagnostic technologies allow for earlier and more accurate identification of individuals at risk, facilitating timely intervention. Furthermore, continued discovery of novel genetic variants and their functional consequences may enable targeted treatments aimed at improving outcomes for individuals affected by ASD. These findings underscore the importance of enhanced prenatal care, including monitoring and management of maternal risk factors, to support optimal neurodevelopment. Future research should prioritize integrative, genetically informed approaches to further elucidate causal mechanisms and advance precision medicine in autism.
- Open Access
- 22 June 2026
- Published by Springer Nature in Rheumatology International
- Vol. 46 (7)
Granulomatosis with polyangiitis presenting with rare urogenital involvement: a case based review
Granulomatosis with polyangiitis (GPA) is a rare systemic necrotizing vasculitis, typically involving the upper and lower respiratory tract and kidneys. Urogenital manifestations are uncommon (< 2%) and frequently mimic malignancy. We describe a female patient in whom GPA initially presented with urogenital manifestations and review the available literature regarding urogenital involvement in the course of GPA. We describe the case of a 58-year-old woman with granulomatosis with polyangiitis initially presenting as a bladder mass, leading to radical cystectomy before the autoimmune etiology was recognized. Over time, the disease evolved to include typical manifestations. Despite multiple relapses under conventional immunosuppression therapy, sustained remission was achieved with rituximab. A literature search of PubMed, Scopus, Embase and Directory of Open Access Journals was performed using predefined keywords related to GPA and urogenital involvement. Exclusion criteria included article language other than English, male patients and kidney involvement. Data were extracted on clinical presentation, diagnostic approach, treatment, and outcomes. We identified 40 female patients with GPA involving the urogenital tract, including our case. The cervix (45%), bladder, and urethra were the most commonly affected sites. In 48 of cases, urogenital involvement was the first manifestation of GPA, frequently mimicking gynecologic or urologic malignancy. Unnecessary surgical interventions were reported in 43% of patients. Corticosteroids and cyclophosphamide were the most commonly used therapies, while rituximab was effective in refractory disease. Urogenital involvement in GPA is rare, often misdiagnosed as malignancy, and associated with significant diagnostic and therapeutic challenges. Heightened awareness of this atypical presentation and early rheumatologic evaluation is crucial to prevent unnecessary invasive procedures. Rituximab represents an effective treatment option in relapsing or refractory cases.
- 22 June 2026
- Published by Springer Nature in Rheumatology International
- Vol. 46 (7)
Open AccessGranulomatosis with polyangiitis presenting with rare urogenital involvement: a case based review
Granulomatosis with polyangiitis (GPA) is a rare systemic necrotizing vasculitis, typically involving the upper and lower respiratory tract and kidneys. Urogenital manifestations are uncommon (< 2%) and frequently mimic malignancy. We describe a female patient in whom GPA initially presented with urogenital manifestations and review the available literature regarding urogenital involvement in the course of GPA. We describe the case of a 58-year-old woman with granulomatosis with polyangiitis initially presenting as a bladder mass, leading to radical cystectomy before the autoimmune etiology was recognized. Over time, the disease evolved to include typical manifestations. Despite multiple relapses under conventional immunosuppression therapy, sustained remission was achieved with rituximab. A literature search of PubMed, Scopus, Embase and Directory of Open Access Journals was performed using predefined keywords related to GPA and urogenital involvement. Exclusion criteria included article language other than English, male patients and kidney involvement. Data were extracted on clinical presentation, diagnostic approach, treatment, and outcomes. We identified 40 female patients with GPA involving the urogenital tract, including our case. The cervix (45%), bladder, and urethra were the most commonly affected sites. In 48 of cases, urogenital involvement was the first manifestation of GPA, frequently mimicking gynecologic or urologic malignancy. Unnecessary surgical interventions were reported in 43% of patients. Corticosteroids and cyclophosphamide were the most commonly used therapies, while rituximab was effective in refractory disease. Urogenital involvement in GPA is rare, often misdiagnosed as malignancy, and associated with significant diagnostic and therapeutic challenges. Heightened awareness of this atypical presentation and early rheumatologic evaluation is crucial to prevent unnecessary invasive procedures. Rituximab represents an effective treatment option in relapsing or refractory cases.
- Open Access
- 8 June 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 5 (1(49))
THE ROLE OF CREATINE SUPPLEMENTATION IN POSTMENOPAUSAL WOMEN - A NARRATIVE REVIEW
Introduction and purpose: Menopause is a phase in a woman’s life characterized by substantial physiological changes resulting from hormonal fluctuations, which can negatively impact bone health, muscle function, and overall physical and cognitive well-being. Creatine is a major factor in regulation of cellular energy metabolism, affecting numerous physiological processes relevant to human health. Current evidence suggests that creatine supplementation may be associated with beneficial effects across a wide range of health outcomes. Therefore, the purpose of this narrative review is to summarize and evaluate the available evidence on the effects of creatine supplementation in postmenopausal women, with particular emphasis on bone health, skeletal muscle function, physical strength, and mental health outcomes. Material and methods: This narrative review summarizes evidence from PubMed-indexed clinical trials, systematic reviews, and meta-analyses examining the potential benefits of creatine supplementation in postmenopausal women. Results: Across the reviewed studies, the findings indicate that creatine may present beneficial effects on various aspects of health in postmenopausal women. In particular, evidence suggests that the composite of creatine supplementation and resistance training may positively determine selected indicators of bone health, skeletal muscle function, and physical strength. Creatine supplementation may be associated with supportive effects on memory and cognitive function. Moreover, emerging evidence indicates a possible supportive role of creatine supplementation in the treatment of depression and sleep-related disorders. Conclusions: Creatine supplementation may provide a practical strategy to help limit bone and muscle loss and to support mental health in postmenopausal women. Future research should focus on clarifying long-term effects and optimal dosing strategies, including larger and more representative cohorts.
- 8 June 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 5 (1(49))
Open AccessTHE ROLE OF CREATINE SUPPLEMENTATION IN POSTMENOPAUSAL WOMEN - A NARRATIVE REVIEW
Introduction and purpose: Menopause is a phase in a woman’s life characterized by substantial physiological changes resulting from hormonal fluctuations, which can negatively impact bone health, muscle function, and overall physical and cognitive well-being. Creatine is a major factor in regulation of cellular energy metabolism, affecting numerous physiological processes relevant to human health. Current evidence suggests that creatine supplementation may be associated with beneficial effects across a wide range of health outcomes. Therefore, the purpose of this narrative review is to summarize and evaluate the available evidence on the effects of creatine supplementation in postmenopausal women, with particular emphasis on bone health, skeletal muscle function, physical strength, and mental health outcomes. Material and methods: This narrative review summarizes evidence from PubMed-indexed clinical trials, systematic reviews, and meta-analyses examining the potential benefits of creatine supplementation in postmenopausal women. Results: Across the reviewed studies, the findings indicate that creatine may present beneficial effects on various aspects of health in postmenopausal women. In particular, evidence suggests that the composite of creatine supplementation and resistance training may positively determine selected indicators of bone health, skeletal muscle function, and physical strength. Creatine supplementation may be associated with supportive effects on memory and cognitive function. Moreover, emerging evidence indicates a possible supportive role of creatine supplementation in the treatment of depression and sleep-related disorders. Conclusions: Creatine supplementation may provide a practical strategy to help limit bone and muscle loss and to support mental health in postmenopausal women. Future research should focus on clarifying long-term effects and optimal dosing strategies, including larger and more representative cohorts.
- Open Access
- 19 March 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 5 (1(49))
GROWING ROLE OF ROBOTIC-ASSISTED SURGERY IN ADULT PATIENTS - A COMPREHENSIVE REVIEW
Introduction: Robotic-Assisted Surgery (RAS) has transitioned from a technological curiosity to a foundation of modern surgery in the last few years. This review aims to evaluate the current status, clinical outcomes, economic implications, and expanding indications of RAS in adult patients across urologic, gynecologic, colorectal, and general surgical disciplines. Methods: A review of the literature was conducted using PubMed, Scopus, and Web of Science databases for English-language articles published up to 2025. The analysis focused on randomized controlled trials (RCTs), systematic reviews, and large-cohort meta-analyses comparing RAS with open surgery and conventional laparoscopy. Results: The analysis indicates that RAS offers superior visualization and improved ergonomics compared to conventional laparoscopy. In urology, RAS has become the gold standard for prostatectomy, showing statistically significant reductions in estimated blood loss (EBL) and improved functional recovery (continence and potency). In gynecology and general surgery, RAS demonstrates lower conversion rates to open surgery, particularly in obese cohorts and deep pelvic dissections. While operative times are frequently longer during the learning curve, total length of hospital stay is consistently reduced. Conclusions: Robotic surgery has proven advantageous in minimizing patient trauma and assisting with complex cases where conventional laparoscopy struggles. The primary barrier remains the high upfront cost; however, these expenses may be offset over time by reduced length of stay and lower complication rates, strengthening the economic case for RAS.
- 19 March 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 5 (1(49))
Open AccessGROWING ROLE OF ROBOTIC-ASSISTED SURGERY IN ADULT PATIENTS - A COMPREHENSIVE REVIEW
Introduction: Robotic-Assisted Surgery (RAS) has transitioned from a technological curiosity to a foundation of modern surgery in the last few years. This review aims to evaluate the current status, clinical outcomes, economic implications, and expanding indications of RAS in adult patients across urologic, gynecologic, colorectal, and general surgical disciplines. Methods: A review of the literature was conducted using PubMed, Scopus, and Web of Science databases for English-language articles published up to 2025. The analysis focused on randomized controlled trials (RCTs), systematic reviews, and large-cohort meta-analyses comparing RAS with open surgery and conventional laparoscopy. Results: The analysis indicates that RAS offers superior visualization and improved ergonomics compared to conventional laparoscopy. In urology, RAS has become the gold standard for prostatectomy, showing statistically significant reductions in estimated blood loss (EBL) and improved functional recovery (continence and potency). In gynecology and general surgery, RAS demonstrates lower conversion rates to open surgery, particularly in obese cohorts and deep pelvic dissections. While operative times are frequently longer during the learning curve, total length of hospital stay is consistently reduced. Conclusions: Robotic surgery has proven advantageous in minimizing patient trauma and assisting with complex cases where conventional laparoscopy struggles. The primary barrier remains the high upfront cost; however, these expenses may be offset over time by reduced length of stay and lower complication rates, strengthening the economic case for RAS.
- Open Access
- 19 March 2026
- Published by Springer Nature in Dermatology and Therapy
- Vol. 16 (5) , 2233-2249
Extragenital Lichen Sclerosus: A Review of the Literature
Lichen sclerosus is a chronic inflammatory disease of the skin and mucous membranes of unknown etiology. The disease most often affects the genital area, but the extragenital form of the disease is diagnosed in approximately 15-20% of patients. Extragenital lichen sclerosus manifests as porcelain-white papules that form plaques. The lesions can enlarge, affecting extensive areas of the skin. Characteristic lesions may be accompanied by hemorrhagic spots, blisters, and erosions. To date, extragenital lichen sclerosus-particularly the bullous variant-poses a therapeutic challenge for clinicians, characterized by high resistance to treatment. The aim of this review is to summarize the currently available knowledge about extragenital lichen sclerosus and its treatment methods.
- 19 March 2026
- Published by Springer Nature in Dermatology and Therapy
- Vol. 16 (5) , 2233-2249
Open AccessExtragenital Lichen Sclerosus: A Review of the Literature
Lichen sclerosus is a chronic inflammatory disease of the skin and mucous membranes of unknown etiology. The disease most often affects the genital area, but the extragenital form of the disease is diagnosed in approximately 15-20% of patients. Extragenital lichen sclerosus manifests as porcelain-white papules that form plaques. The lesions can enlarge, affecting extensive areas of the skin. Characteristic lesions may be accompanied by hemorrhagic spots, blisters, and erosions. To date, extragenital lichen sclerosus-particularly the bullous variant-poses a therapeutic challenge for clinicians, characterized by high resistance to treatment. The aim of this review is to summarize the currently available knowledge about extragenital lichen sclerosus and its treatment methods.
- Open Access
- 14 February 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 51
Carbohydrate Mouth Rinsing in Recreational Athletes: A Narrative Review of Performance Effects, Mechanisms, and Gastrointestinal Implications
Background: Carbohydrate mouth rinsing (CMR) offers potential for athletes seeking performance benefits while minimizing gastrointestinal issues. Unlike the usual method of carbohydrate consumption, CMR allows athletes to swish carbohydrate solutions in their mouths without swallowing, which may trigger central mechanisms that enhance performance while avoiding GI problems. Aim: To review the current evidence regarding carbohydrate mouth rinsing effects on athletic performance and GI safety in recreational athletes. Material and Methods: A narrative review of peer-reviewed literature from examining CMR effects on exercise performance, cognitive function, and gastrointestinal outcomes. Data synthesis focused on the mechanism of action, performance outcomes, and practical applications for recreational athletes. Results: Meta-analytical evidence demonstrates modest ergogenic effects of CMR across exercise modalities. Optimal protocols utilize 6-6.5% maltodextrin solutions rinsed for ≤10 seconds. CMR effectiveness is enhanced under fed conditions during aerobic exercise. CMR reduces exercise-induced gastrointestinal symptoms while enhancing high-intensity muscular endurance. Preliminary evidence suggests cognitive performance benefits when combined with caffeine, though certainty remains low. Conclusions: Carbohydrate mouth rinsing is a simple yet effective ergogenic aid for recreational athletes, and it can be easily integrated into their routines. Using CMR before and during moderate-to-high-intensity workouts can enhance exercise capacity and performance while avoiding the gastrointestinal issues that often accompany carbohydrate intake. Since CMR offers a performance boost without the discomfort of GI distress, it stands out as a practical nutritional strategy for athletes. Moving forward, research should examine how men and women respond to CMR, how regular use may lead to chronic adaptations, and how best to tailor CMR strategies for different athletic groups.
- 14 February 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 51
Open AccessCarbohydrate Mouth Rinsing in Recreational Athletes: A Narrative Review of Performance Effects, Mechanisms, and Gastrointestinal Implications
Background: Carbohydrate mouth rinsing (CMR) offers potential for athletes seeking performance benefits while minimizing gastrointestinal issues. Unlike the usual method of carbohydrate consumption, CMR allows athletes to swish carbohydrate solutions in their mouths without swallowing, which may trigger central mechanisms that enhance performance while avoiding GI problems. Aim: To review the current evidence regarding carbohydrate mouth rinsing effects on athletic performance and GI safety in recreational athletes. Material and Methods: A narrative review of peer-reviewed literature from examining CMR effects on exercise performance, cognitive function, and gastrointestinal outcomes. Data synthesis focused on the mechanism of action, performance outcomes, and practical applications for recreational athletes. Results: Meta-analytical evidence demonstrates modest ergogenic effects of CMR across exercise modalities. Optimal protocols utilize 6-6.5% maltodextrin solutions rinsed for ≤10 seconds. CMR effectiveness is enhanced under fed conditions during aerobic exercise. CMR reduces exercise-induced gastrointestinal symptoms while enhancing high-intensity muscular endurance. Preliminary evidence suggests cognitive performance benefits when combined with caffeine, though certainty remains low. Conclusions: Carbohydrate mouth rinsing is a simple yet effective ergogenic aid for recreational athletes, and it can be easily integrated into their routines. Using CMR before and during moderate-to-high-intensity workouts can enhance exercise capacity and performance while avoiding the gastrointestinal issues that often accompany carbohydrate intake. Since CMR offers a performance boost without the discomfort of GI distress, it stands out as a practical nutritional strategy for athletes. Moving forward, research should examine how men and women respond to CMR, how regular use may lead to chronic adaptations, and how best to tailor CMR strategies for different athletic groups.
- Open Access
- 6 January 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- No. 1(49)
MODERN BIOLOGICAL TREATMENT METHODS FOR ALOPECIA AREATA: A COMPREHENSIVE REVIEW
Introduction: Alopecia areata (AA) is a chronic, immune-mediated hair-loss disorder driven by cytotoxic T-cell activation and loss of hair-follicle immune privilege. Janus kinase (JAK) inhibitors and emerging targeted biologics have reshaped treatment options for moderate-to-severe AA. This review compared three approved JAK-based therapies (ritlecitinib, baricitinib, deuruxolitinib) and summarized evidence on investigational biologic agents. Materials and Methods: This narrative review was based on a structured search of PubMed and Google Scholar for English-language publications available up to 2025. Search terms included “alopecia areata,” “biologic therapy,” “JAK inhibitors,” “ritlecitinib,” “baricitinib,” “deuruxolitinib,” and “immunomodulation.” Phase 2 and 3 trials, early-phase studies, observational research, and review articles were screened. Full texts were assessed to extract information on mechanisms of action, JAK-isoform selectivity, clinical efficacy measured by SALT outcomes, safety, and emerging therapeutic strategies. Results: All three JAK inhibitors showed significant efficacy compared with placebo but differed in selectivity and response dynamics. Ritlecitinib (JAK3/TEC) demonstrated a rapid onset of action and a favorable safety profile. Baricitinib (JAK1/2) produced gradual, sustained improvement supported by extensive long-term data. Deuruxolitinib (JAK1/2/TYK2) achieved high SALT ≤20 response rates across THRIVE-AA trials. Emerging biologics such as bempikibart (anti–IL-7Rα) and early investigational agents (ALD-102, DR-01) showed preliminary efficacy, though evidence remains limited by short follow-up and lack of predictive biomarkers. Conclusions: JAK inhibitors constitute a major therapeutic advance for moderate-to-severe AA, providing meaningful clinical benefit with acceptable safety. Novel biologic agents may offer more selective and durable immune modulation. Long-term studies and development of precision-medicine approaches will be essential to optimize future AA management.
- 6 January 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- No. 1(49)
Open AccessMODERN BIOLOGICAL TREATMENT METHODS FOR ALOPECIA AREATA: A COMPREHENSIVE REVIEW
Introduction: Alopecia areata (AA) is a chronic, immune-mediated hair-loss disorder driven by cytotoxic T-cell activation and loss of hair-follicle immune privilege. Janus kinase (JAK) inhibitors and emerging targeted biologics have reshaped treatment options for moderate-to-severe AA. This review compared three approved JAK-based therapies (ritlecitinib, baricitinib, deuruxolitinib) and summarized evidence on investigational biologic agents. Materials and Methods: This narrative review was based on a structured search of PubMed and Google Scholar for English-language publications available up to 2025. Search terms included “alopecia areata,” “biologic therapy,” “JAK inhibitors,” “ritlecitinib,” “baricitinib,” “deuruxolitinib,” and “immunomodulation.” Phase 2 and 3 trials, early-phase studies, observational research, and review articles were screened. Full texts were assessed to extract information on mechanisms of action, JAK-isoform selectivity, clinical efficacy measured by SALT outcomes, safety, and emerging therapeutic strategies. Results: All three JAK inhibitors showed significant efficacy compared with placebo but differed in selectivity and response dynamics. Ritlecitinib (JAK3/TEC) demonstrated a rapid onset of action and a favorable safety profile. Baricitinib (JAK1/2) produced gradual, sustained improvement supported by extensive long-term data. Deuruxolitinib (JAK1/2/TYK2) achieved high SALT ≤20 response rates across THRIVE-AA trials. Emerging biologics such as bempikibart (anti–IL-7Rα) and early investigational agents (ALD-102, DR-01) showed preliminary efficacy, though evidence remains limited by short follow-up and lack of predictive biomarkers. Conclusions: JAK inhibitors constitute a major therapeutic advance for moderate-to-severe AA, providing meaningful clinical benefit with acceptable safety. Novel biologic agents may offer more selective and durable immune modulation. Long-term studies and development of precision-medicine approaches will be essential to optimize future AA management.
- 10 November 2025
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 40 (7)
Understanding socioeconomic outcomes in Danish children with moderate‐to‐severe atopic dermatitis
- 10 November 2025
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 40 (7)
Understanding socioeconomic outcomes in Danish children with moderate‐to‐severe atopic dermatitis